Industry Insights
-
Tackling Special Characters With SAS And R
9/3/2025
Protect the integrity of your research by proactively detecting and removing hidden characters to ensure accurate, reliable, and compliant study results.
-
Ocular Endpoint Protection In A Capital-Constrained Market
9/3/2025
Ocular Endpoint Protection reframes data capture as a non-negotiable driver of efficiency, and sponsors who embed point-of-need (PON) into their protocols protect both their investment and results.
-
Scout Belongs In Your eClinical Solution Suite
9/3/2025
Traditional eClinical platforms manage data, but not participation. Learn how to fill the gap with travel, payments, and support that keep patients engaged, sites focused, and trials moving forward.
-
The Hidden Cost Of Transactional Burden: It's Time For Sites To Speak Up
9/3/2025
Transactional burdens weigh heavily on sites, straining trust with sponsors and patients. See why site voices matter and how sounding off can strengthen clinical trial relationships.
-
Global Trials Can't Afford To Overlook Africa
9/3/2025
Africa’s trial capacity is growing, but patient services remain the key to retention and reliable outcomes. Sponsors that act now can shape Africa into a true global trial hub.
-
Navigating Autoimmune Disease A Playbook For Cell And Gene Therapies
9/3/2025
By integrating site readiness, patient engagement, and data-driven decision-making, the cell and gene therapies (CAGT) field is advancing toward therapies that not only control disease but transform lives.
-
Five Questions Biotechs Should Ask Before Selecting A Bioanalytical CRO
9/2/2025
In a landscape where speed, quality, and trust are inseparable, choosing a CRO that shares your ambition is not optional—it is essential to survival and success.
-
Accelerating IND-Enabling Studies With Automated Bioanalysis Workflows
9/2/2025
Reimagined as automation-first, bioanalysis shifts from being an Investigational New Drug (IND) bottleneck to a catalyst for innovation—helping companies move therapies forward with greater confidence.
-
Why Bioanalysis Needs To Break Free From Manual Bottlenecks
9/2/2025
Bioanalysis remains one of the most persistent bottlenecks in drug development, with CRO's displaying inefficiencies that are no longer operational nuisances but strategic liabilities.
-
How Digital Twins Are Rewriting Clinical Trials
9/2/2025
While the benefits of digital twins to accelerate clinical trials are undeniable, many questions about their use are still unanswered and go far beyond technology.